Overview
NICE is unable to make a recommendation about the use in the NHS of regorafenib for metastatic colorectal cancer after treatment for metastatic disease because no evidence submission was received from Bayer for the technology.
Last reviewed: 25 February 2015
Next review: We will review this decision if the company decides to make a submission.